CHAMPIONS ONCOLOGY INC (CSBR) Stock Fundamental Analysis
NASDAQ:CSBR - Nasdaq - US15870P3073 - Common Stock - Currency: USD
CSBR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 56 industry peers in the Life Sciences Tools & Services industry. CSBR has a medium profitability rating, but doesn't score so well on its financial health evaluation. CSBR is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
CSBR had positive earnings in the past year.
CSBR had a negative operating cash flow in the past year.
In multiple years CSBR reported negative net income over the last 5 years.
In multiple years CSBR reported negative operating cash flow during the last 5 years.
1.2 Ratios
CSBR has a better Return On Assets (20.98%) than 96.43% of its industry peers.
The Return On Equity of CSBR (117.52%) is better than 100.00% of its industry peers.
The Return On Invested Capital of CSBR (49.38%) is better than 98.21% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.98% | ||
| ROE | 117.52% | ||
| ROIC | 49.38% |
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 10.97%, CSBR belongs to the top of the industry, outperforming 85.71% of the companies in the same industry.
CSBR has a better Operating Margin (11.48%) than 66.07% of its industry peers.
CSBR has a Gross Margin (51.58%) which is in line with its industry peers.
In the last couple of years the Gross Margin of CSBR has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 11.48% | ||
| PM (TTM) | 10.97% | ||
| GM | 51.58% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
2. Health
2.1 Basic Checks
CSBR has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
CSBR has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CSBR has more shares outstanding
There is no outstanding debt for CSBR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of 1.54, we must say that CSBR is in the distress zone and has some risk of bankruptcy.
CSBR has a Altman-Z score (1.54) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.02 indicates that CSBR is not too dependend on debt financing.
CSBR has a better Debt to Equity ratio (0.02) than 67.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.54 |
ROIC/WACC4.82
WACC10.24%
2.3 Liquidity
CSBR has a Current Ratio of 0.99. This is a bad value and indicates that CSBR is not financially healthy enough and could expect problems in meeting its short term obligations.
The Current ratio of CSBR (0.99) is worse than 87.50% of its industry peers.
A Quick Ratio of 0.99 indicates that CSBR may have some problems paying its short term obligations.
Looking at the Quick ratio, with a value of 0.99, CSBR is doing worse than 80.36% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
CSBR shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 176.81%, which is quite impressive.
CSBR shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.03%.
Measured over the past years, CSBR shows a quite strong growth in Revenue. The Revenue has been growing by 13.13% on average per year.
EPS 1Y (TTM)176.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
Revenue 1Y (TTM)19.03%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%41.77%
3.2 Future
The Earnings Per Share is expected to grow by 56.78% on average over the next years. This is a very strong growth
Based on estimates for the next years, CSBR will show a quite strong growth in Revenue. The Revenue will grow by 17.84% on average per year.
EPS Next Y162.45%
EPS Next 2Y56.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year15.88%
Revenue Next 2Y11.77%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 14.19, the valuation of CSBR can be described as correct.
Compared to the rest of the industry, the Price/Earnings ratio of CSBR indicates a rather cheap valuation: CSBR is cheaper than 91.07% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of CSBR to the average of the S&P500 Index (28.98), we can say CSBR is valued rather cheaply.
With a Price/Forward Earnings ratio of 33.51, CSBR can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Forward Earnings ratio of CSBR is on the same level as its industry peers.
CSBR's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 21.38.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.19 | ||
| Fwd PE | 33.51 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, CSBR is valued cheaply inside the industry as 91.07% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 11.99 |
4.3 Compensation for Growth
CSBR's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
CSBR's earnings are expected to grow with 56.78% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y56.78%
EPS Next 3YN/A
5. Dividend
5.1 Amount
No dividends for CSBR!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:CSBR (4/29/2025, 8:00:01 PM)
7.52
+0.21 (+2.87%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners47.82%
Inst Owner Change0%
Ins Owners25.86%
Ins Owner Change2.28%
Market Cap104.00M
Analysts82.86
Price Target12.24 (62.77%)
Short Float %1.42%
Short Ratio3.64
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2009.8%
Min EPS beat(2)390.2%
Max EPS beat(2)3629.41%
EPS beat(4)4
Avg EPS beat(4)1146.3%
Min EPS beat(4)106.13%
Max EPS beat(4)3629.41%
EPS beat(8)5
Avg EPS beat(8)540.78%
EPS beat(12)6
Avg EPS beat(12)292.36%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)15.24%
Min Revenue beat(2)1.31%
Max Revenue beat(2)29.17%
Revenue beat(4)4
Avg Revenue beat(4)10.71%
Min Revenue beat(4)1.31%
Max Revenue beat(4)29.17%
Revenue beat(8)4
Avg Revenue beat(8)1.57%
Revenue beat(12)6
Avg Revenue beat(12)0.9%
Revenue beat(16)10
Avg Revenue beat(16)1.14%
PT rev (1m)0%
PT rev (3m)50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-1100%
EPS NY rev (1m)0%
EPS NY rev (3m)42.86%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.18%
Revenue NY rev (1m)0.8%
Revenue NY rev (3m)0.8%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.19 | ||
| Fwd PE | 33.51 | ||
| P/S | 1.78 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 19.02 | ||
| P/tB | 20.26 | ||
| EV/EBITDA | 11.99 |
EPS(TTM)0.53
EY7.05%
EPS(NY)0.22
Fwd EY2.98%
FCF(TTM)-0.1
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS4.24
BVpS0.4
TBVpS0.37
PEG (NY)0.09
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.98% | ||
| ROE | 117.52% | ||
| ROCE | 62.51% | ||
| ROIC | 49.38% | ||
| ROICexc | 70.31% | ||
| ROICexgc | 73.57% | ||
| OM | 11.48% | ||
| PM (TTM) | 10.97% | ||
| GM | 51.58% | ||
| FCFM | N/A |
ROA(3y)-13.95%
ROA(5y)-10.02%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.65%
GM growth 5Y-2.63%
F-Score5
Asset Turnover1.91
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 0.01 | ||
| Cap/Depr | 1.47% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 0.99 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 1.54 |
F-Score5
WACC10.24%
ROIC/WACC4.82
Cap/Depr(3y)106.12%
Cap/Depr(5y)172.76%
Cap/Sales(3y)3.95%
Cap/Sales(5y)5.35%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)176.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%325%
EPS Next Y162.45%
EPS Next 2Y56.78%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)19.03%
Revenue growth 3Y6.91%
Revenue growth 5Y13.13%
Sales Q2Q%41.77%
Revenue Next Year15.88%
Revenue Next 2Y11.77%
Revenue Next 3Y17.89%
Revenue Next 5Y17.84%
EBIT growth 1Y176.48%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year162.59%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-146.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-123.77%
OCF growth 3YN/A
OCF growth 5YN/A